A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia
Chatchada Karanes(Erasmus MC Cancer Institute), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michael R. Grever(The Ohio State University Wexner Medical Center), David R. Head(University of Southern California), Kenneth J. Kopecky(City Of Hope National Medical Center), Eric H. Kraut(The Ohio State University), Alan Lichtin(Cleveland Clinic), Harry E. Hynes, Richard Vial(Louisiana State University), Sucha Nand(Loyola University Medical Center), Wolfram E. Samlowski(University of Utah)
Cited by 88
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k